We believe this work provides insight into the role of topoisomerase II beta in gene regulation, and cancer patient risk for cardiovascular disease. [4/4]

We compared the effects of CX and DOX in human cardiomyocytes. CX is 20-fold less toxic than DOX and induces an order of magnitude fewer changes in gene expression despite a shared target. However, CX-induced transcriptional changes are shared with DOX. [3/4]

DOX is an effective anti-cancer drug. However, it inhibits the DNA topology regulator topoisomerase II beta in the heart leading to increased risk for cardiovascular disease. CX-5461 is a promising novel anti-cancer compound that was recently shown to target the same protein. [2/4]

Project led by Sayan investigating the effects of CX-5461, an anti-cancer drug currently in clinical trials, on cardiomyocytes: ‘Topoisomerase II inhibitors CX-5461 and Doxorubicin differ in their cardiotoxicity profiles.’ [1/4] www.biorxiv.org/content/10.1...

Happy to share our work led by Renee: ‘Anthracyclines induce global changes in cardiomyocyte chromatin accessibility that overlap with cardiovascular disease loci.’
www.biorxiv.org/content/10.1...

Congrats Anat, Nehal and Guy!

Congrats Ben!

Happy to share the published version of Omar & Sayan’s paper. We generated a DNA-damage-associated cardiomyocyte protein co-expression network to gain insights into tolerance to genetic variation and disease. www.sciencedirect.com/science/arti...

Congrats Tauras!

Come join us at #ASHG25 in Boston Oct 14-18! Abstract submission site (ashg.org/submit) is now live. Abstracts due June 9th.